Recent Updates
Recently added Catalysts
NERV Positive Sentiment

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

Key Takeaway: Minerva Neurosciences, Inc. will participate in two investor conferences in September 2026. The Wells Fargo Healthcare Conference will take place on September 8, followed by the Cantor Global Healthcare Conference on September 9. Management will engage in 1x1 meetings and a fireside chat, highlighting their focus on CNS disorders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Minerva is actively engaging with investors at two major conferences.
  • Participation in high-profile events indicates confidence in their pipeline.
  • The company is focused on developing therapies for CNS disorders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+355%
120-day peak, hindsight
Typical move
29.3%
average across 2 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
MIN-117
Phase 2 · Major Depressive Disorder

Full Press Release Details

BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences.

Wells Fargo Healthcare Conference Date: Tuesday, September 8 Format: 1x1 meetings Location: New York, NY

2026 Cantor Global Healthcare Conference Date: Wednesday, September 9 Format: Fireside chat and 1x1 meetings Time: 2:45 – 3:15 PM EDT Location: New York, NY
If you are interested in meeting with the Minerva team during the conferences, please reach out to your respective conference representative.
The live webcast can be accessed in the events section of the Minerva Neurosciences website HERE. Access to the webcast replay will be available approximately two hours after the completion of the events and will be archived on the Company’s website.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is conducting a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.

Contacts: Frederick Ahlholm Chief Financial Officer Minerva Neurosciences, Inc. FAhlholm@minervaneurosciences.com

Corey Davis, Ph.D. LifeSci Advisors, LLC 212-915-2577 cdavis@lifesciadvisors.com

Frequently Asked Questions

When will Minerva participate in the investor conferences?

Minerva will participate in the Wells Fargo Healthcare Conference on September 8 and the Cantor Global Healthcare Conference on September 9.

What formats will the conferences include?

The conferences will feature 1x1 meetings and a fireside chat.

Where are the conferences taking place?

Both conferences will be held in New York, NY.

What is Minerva's focus as a biopharmaceutical company?

Minerva focuses on developing therapies for central nervous system disorders.

Last updated: Aug 28, 2026